Lung Cancer RNA Panel
Cat Number: LUNG-RT48
The Lung Cancer RNA Panel is a RT-qPCR assay that detects ALK, ROS1, and RET fusion genes, as well as MET exon 14 skipping mutations, which are key oncogenic drivers in non-small cell lung cancer and important for targeted therapy selection.
- 48 tests per kit
- 2-hour turnaround time
- Works with FFPE and fresh frozen samples
- 8 Reactions per sample
- For research use (RUO) in the U.S
- For in vitro diagnostic use (IVD) in the European Union
Fusion genes involving ALK, ROS1, and RET, as well as MET exon 14 skipping mutations, are key oncogenic drivers in non-small cell lung cancer (NSCLC). These genetic alterations result from chromosomal translocations leading to abnormal activation of tyrosine kinase signaling pathways that drive tumor growth. While ALK, ROS1, and RET fusions occur in a subset of NSCLC patients (3-7%, ~2%, and ~1%, respectively), MET exon 14 skipping mutations are detected in 3-4% of lung adenocarcinoma cases. Identifying these alterations is critical, as patients with these mutations may benefit from targeted therapies such as crizotinib, vandetanib, and cabozantinib, which have shown significant clinical efficacy.
The Lung Cancer RNA Panel is a one-step RT-qPCR assay designed for the qualitative detection of ALK, ROS1, and RET fusion genes, as well as MET exon 14 skipping mutations. The assay employs a proprietary enzyme/buffer mix, enabling simultaneous reverse transcription and amplification of target sequences in a single reaction. Using fluorescent probes for precise mutation detection and an endogenous control gene for quality assessment, this panel ensures reliable and high-sensitivity results.
The kit is optimized for use with RNA isolated from tumor biopsies, FFPE samples, and fresh-frozen tissues.
The Lung Cancer RNA Panel provides a streamlined workflow and highly accurate molecular profiling, making it an essential tool for oncologists, pathologists, and researchers focused on precision medicine in lung cancer.
| Fusion Gene Variant | Chromosomal Translocation | Primer No. |
| EML4-ALK | E13;A20 | 1 |
| E20;A20 | 1 | |
| E20;ins18A20 | 1 | |
| E6;A20 | 1 | |
| E6ins33;A20 | 1 | |
| E6;ins18A20 | 1 | |
| E14ins11;del49A20 | 2 | |
| E2;A20 | 3 | |
| E2;ins117A20 | 3 | |
| E13;ins69A20 | 1 | |
| E14;del14A20 | 2 | |
| E14;del36A20 | 2 | |
| E17;ins30A20 | 3 | |
| E17ins61;ins34A20 | 3 | |
| E17del58ins39;A20 | 3 | |
| E17ins65;A20 | 3 | |
| E17;ins68A20 | 3 | |
| E15del60;del71A20 | 2 | |
| E18;A20 | 3 | |
| E3;ins53A20 | 3 | |
| E6;A19 | 1 | |
| SLC34A2-ROS1 | S4;R32 | 6 |
| S13del;R32 | 6 | |
| S4;R34 | 5 | |
| S13del;R34 | 5 | |
| CD74-ROS1 | C6;R32 | 6 |
| C7;R32 | 6 | |
| C6;R34 | 5 | |
| SDC4-ROS1 | S2;R32 | 6 |
| S4;R32 | 6 | |
| S4;R34 | 5 | |
| EZR-ROS1 | E10;R34 | 5 |
| LRIG3-ROS1 | L16;R35 | 7 |
| TPM3-ROS1 | T8;R35 | 7 |
| GOPC-ROS1 | G7;R35 | 7 |
| G4;R36 | 4 | |
| KIF5B-RET | K15;R12 | 4 |
| K16;R12 | 4 | |
| K22;R12 | 4 | |
| K23;R12 | 4 | |
| K24;R8 | 5 | |
| K24;R11 | 5 | |
| K15;R11 | 7 | |
| CCDC6-RET | C1;R12 | 8 |
| NCOA4-RET | N6;R12 | 8 |
| TRIM33-RET | T14;R12 | 8 |
| Gene | Mutation | Primer No. |
| MET | Exon 14 Skipping | 3 |
The Lung Cancer RNA Panel follows a streamlined and efficient workflow, allowing for mutation detection in approximately 2 hours with minimal complexity.
EntroGen’s Lung Cancer RNA Panel requires a real-time PCR instrument capable of detecting FAM, VIC, and CY5 fluorescent probes. The kit includes all necessary reagents for PCR amplification and detection, along with validated reaction controls to ensure reliable results.
RNA isolation columns and reagents are not included.
 |
Webinar Recording: RNA Based NGS & RT-PCR Alternatives for Fusion Gene Detection in Solid Tumors |
Click to download lot-specific quality control data for your product:
